Form 4: BioAffinity Technologies VP Acquires 100,000 Shares of Common Stock

James Michael Edwards, VP and CFO of bioAffinity Technologies, acquired 100,000 shares of common stock on November 5, 2024, through a grant of restricted shares.

Summary

• On November 5, 2024, James Michael Edwards, VP and CFO of bioAffinity Technologies, acquired 100,000 shares of common stock.
• The acquisition was a grant of restricted shares.
• These shares will vest 25% on the grant date, the one-year anniversary, the two-year anniversary, and the three-year anniversary of the grant date.
• Following the transaction, Edwards beneficially owns 113,956 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by an executive. The vesting schedule suggests a long-term commitment.

Positives

• The grant of restricted shares aligns the executive's interests with the long-term performance of the company.

Future Outlook

The vesting schedule of the restricted shares extends over three years, suggesting a long-term commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a grant of restricted stock, a common practice for incentivizing executives.

Stakeholder Impact

• The acquisition of shares by a key executive could be viewed positively by shareholders, as it aligns management's interests with the company's performance.

Key Dates

Keywords

bioAffinity Technologies, BIAF, James Michael Edwards, stock acquisition, restricted shares, Form 4, officer, CFO, beneficial ownership